More on EDIT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.44 |
|
|||
| Open | $2.44 | ||||
| 52 Wk High | $43.99 | ||||
| 52 Wk Low | $12.43 | ||||
| Day High | $2.47 | ||||
| Day Low | $2.33 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,552,416 | ||||
- Editas Medicine to present LNP research at ESGCT congress in October
- Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
- Wells Fargo Upgrades Editas Medicine (EDIT) to Equal Weight
- Form 8-K Editas Medicine, Inc. For: Oct 08
- Editas Medicine clears first-in-human trial of EDIT-401 in Australia
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
- Guggenheim Upgrades Editas Medicine (EDIT) to Buy
- Editas Medicine grants stock options to new chief medical officer
- Editas Medicine Reports Inducement Grants to New Chief Medical Officer
- Editas Medicine names Dan Ory as chief medical officer
Entities mentioned with EDIT
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- ARK | View Related Stories »
- Morgan Stanley | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
